Amicus Therapeutics (NASDAQ:FOLD) Upgraded at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other brokerages have also recently weighed in on FOLD. Cantor Fitzgerald upped their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Bank of America upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Guggenheim upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.66 on Friday. Amicus Therapeutics has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $2.89 billion, a PE ratio of -28.41 and a beta of 0.68. The firm has a 50-day moving average price of $10.96 and a 200 day moving average price of $10.61.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 30,401 shares of company stock valued at $352,038. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of FOLD. Wellington Management Group LLP raised its holdings in Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares during the period. Janus Henderson Group PLC raised its holdings in Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after purchasing an additional 2,307,385 shares during the period. William Blair Investment Management LLC raised its holdings in Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after purchasing an additional 1,477,084 shares during the period. Geode Capital Management LLC raised its holdings in Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock worth $70,499,000 after purchasing an additional 80,926 shares during the period. Finally, Fiera Capital Corp raised its holdings in Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.